Thomas P. Leist, MD, PhD, FAAN
Professor
Division Chief, Multiple Sclerosis/Neuroimmunology
Fellowship Program Director, Multiple Sclerosis/Neuroimmunology

Contact
900 Walnut Street
Second Floor
Philadelphia, PA 19107
215-955-6871
215-503-2990 fax
Thomas P. Leist, MD, PhD, FAAN
Professor
Division Chief, Multiple Sclerosis/Neuroimmunology
Fellowship Program Director, Multiple Sclerosis/Neuroimmunology
Education
Medical School
MD, University of Miami School of Medicine
PhD, University of Zurich, Switzerland
Residency
Cornell Medical CenterÂ
Fellowship
National Institute of Health
UCLA
Univesity of Zurich, Switzerland
Publications
- Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary
- Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
- Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
- Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: A plain language summary
- T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy
Board Certification
Neurology
Hospital Appointment
Thomas Jefferson University Hospital